RXDX-105
Teva and Ignyta shake hands in oncology deal
March 19, 2015Research and Development, Sales and Marketing CEP-32496, CEP-40125, Levact, RXDX-105, Teva, ignyta, oncology
Ignyta has acquired four oncology R&D assets from Israeli pharma generics giant Teva in a deal worth around $42 million. …
